Cetera Trust Company N.A Makes New Investment in Halozyme Therapeutics, Inc. $HALO

Cetera Trust Company N.A bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 6,250 shares of the biopharmaceutical company’s stock, valued at approximately $489,000.

Several other large investors have also modified their holdings of HALO. Measured Wealth Private Client Group LLC increased its position in shares of Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares during the last quarter. Larson Financial Group LLC raised its holdings in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares during the period. MidFirst Bank acquired a new position in Halozyme Therapeutics in the second quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Halozyme Therapeutics in the second quarter valued at about $28,000. Finally, Quantbot Technologies LP purchased a new position in Halozyme Therapeutics during the second quarter worth about $30,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 0.4%

Shares of Halozyme Therapeutics stock opened at $108.64 on Tuesday. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $109.10. The company has a market capitalization of $12.33 billion, a P/E ratio of 32.43, a P/E/G ratio of 0.43 and a beta of 0.85. The company has a 50 day moving average of $83.94 and a 200 day moving average of $73.96.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company’s revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts forecast that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $79,987,320.40. This trade represents a 2.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the sale, the director owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 64,103 shares of company stock valued at $5,226,496. 2.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Morgan Stanley dropped their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Weiss Ratings cut shares of Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, August 14th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Finally, TD Cowen boosted their target price on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $91.20.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.